Immunological analysis revealed that SAT1 inhibition reduces neutrophil recruitment to tumors, consequently impairing angiogenesis and tumor growth, thereby identifying a novel metabolic target for cancer immunotherapy (Kato et al., 2023). The gene discussed is SAT1; the disease is neoplasm.